Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLAM vs 7+3 for Newly Diagnosed AML
NCT01349972Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2011
- Primary completion
- May 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of alvocidib in acute myeloid leukemia (AML) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Complete Response Rate at 3 years. Started Apr 2011; status: completed.
02
Drugs
alvocidib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01349972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01349972.